Lifecore (LFCR) Biomedical announced that it has signed an agreement with a leading global pharmaceutical company. Under the terms of the agreement, Lifecore will transfer the commercial manufacturing for a leading injectable pharmaceutical product from the current manufacturer to Lifecore’s facilities. Upon completion of the transfer and satisfaction of all regulatory requirements, Lifecore will be the commercial supplier of choice for the product. This is the second agreement that Lifecore has signed with the same multinational organization in recent months, highlighting the company’s growing reputation for technical excellence, quality, and reliability in sterile injectables.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFCR:
- Lifecore, PolyPeptide collab to offer peptide manufacturing solution
- Lifecore Biomedical, Inc. (LFCR) Q1 Earnings Cheat Sheet
- Lifecore Biomedical Approves New Cash Incentive Plan
- Hold Rating for Lifecore Biomedical Amid Strategic Progress and High Leverage Concerns
- Lifecore files to sell $150M of common stock, warrants